This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
Ublituximab for the treatment of CD20 positive B-cell malignancies
- Hani M. Babiker, Ashley E. Glode, Laurence S. Cooke, Daruka Mahadevan
- Expert Opinion on Investigational Drugs, April 2018, Taylor & Francis
- DOI: 10.1080/13543784.2018.1459560
